Breast cancer Cancer Malignant neoplasm of the breast
Conditions
Interventions
Current interventions as of 09/04/2024:
There are no trial drugs or treatments associated with this observational study. Long-term follow-up data will be collected for this Research Database for the f
not angina or transient ischaemic attack), all hip fractures, and fractures leading to an overnight stay in hospital.
Note: From 2019 onwards, follow-up data will continue to be collected solely via
Sponsors
Queen Mary University of London (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Patients randomised to one of the monotherapy arms in the ATAC trial (randomised to the ATAC trial during the period 1996 - 2003 and were female, post-menopausal and 45 years and above at the time of randomisation) 2. Alive at 10 years follow-up
Exclusion criteria
Exclusion criteria: 1. Patients who have withdrawn consent to participate in the ATAC trial or this study 2. Where the LATTE Executive Committee determines that there is no possibility of obtaining follow-up
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| To compare the long-term effects of tamoxifen (20 mg once daily [od]) and anastrozole (1 mg od) which were given in the ATAC trial (and who have all now completed treatment) as adjuvant therapy in terms of: 1. Time to distant recurrence 2. Cancer-specific survival 3. New breast primaries 4. Other cancers 5. Ischaemic cardiac and cerebrovascular events 6. Hip (and other) fractures | — |
Primary
| Measure | Time frame |
|---|---|
| Time to recurrence of breast cancer in the post 10 year period (defined as the earliest of local or distant recurrence, new primary breast cancer, or death). | — |
Countries
Australia, Belgium, Canada, England, France, Germany, Italy, Netherlands, New Zealand, South Africa, Sweden, United Kingdom, United States of America
Outcome results
None listed